Cargando…

Editorial: Neutralizing Antibodies in the Prevention and Treatment of COVID-19

Detalles Bibliográficos
Autores principales:	Razonable, Raymund R., Chen, Peter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9198713/ https://www.ncbi.nlm.nih.gov/pubmed/35720338 http://dx.doi.org/10.3389/fimmu.2022.938069

Ejemplares similares

Editorial: Novel Concepts in Using Broadly Neutralizing Antibodies for HIV-1 Treatment and Prevention
por: Wagh, Kshitij, et al.
Publicado: (2021)

Clinical Prioritization of Antispike Monoclonal Antibody Treatment of Mild to Moderate COVID-19
por: Razonable, Raymund R., et al.
Publicado: (2022)

COVID-19 and Solid Organ Transplantation: Role of Anti-SARS-CoV-2 Monoclonal Antibodies
por: Dhand, Abhay, et al.
Publicado: (2022)

Editorial: Tolerating Factor VIII: Novel Strategies to Prevent and Reverse Neutralizing Anti-FVIII Antibodies
por: Lacroix-Desmazes, Sébastien, et al.
Publicado: (2021)

Broadly Neutralizing Antibodies for HIV-1 Prevention
por: Walsh, Stephen R., et al.
Publicado: (2021)

Editorial: HIV-Induced Damage of B Cells and Production of HIV Neutralizing Antibodies
por: Chiodi, Francesca, et al.
Publicado: (2018)

Neutralizing antibodies for the prevention and treatment of COVID-19
por: Du, Lanying, et al.
Publicado: (2021)

Contribution to HIV Prevention and Treatment by Antibody-Mediated Effector Function and Advances in Broadly Neutralizing Antibody Delivery by Vectored Immunoprophylaxis
por: Phelps, Meredith, et al.
Publicado: (2021)

Neutralizing monoclonal antibodies for COVID-19 treatment and prevention
por: Jaworski, Juan Pablo
Publicado: (2021)

Considerations for the Feasibility of Neutralizing Antibodies as a Surrogate Endpoint for COVID-19 Vaccines
por: Liu, Jianyang, et al.
Publicado: (2022)

Stewardship of COVID-19 volunteers by nested trial design
por: Gottlieb, Robert L, et al.
Publicado: (2022)

Neutralizing Monoclonal Antibody Use and COVID-19 Infection Outcomes
por: Ambrose, Nalini, et al.
Publicado: (2023)

Breakthrough COVID-19 and casirivimab-imdevimab treatment during a SARS-CoV-2 B1.617.2 (Delta) surge
por: Bierle, Dennis M., et al.
Publicado: (2021)

Letermovir for the prevention of cytomegalovirus infection and disease in transplant recipients: an evidence-based review
por: El Helou, Guy, et al.
Publicado: (2019)

Editorial: Antibody Therapeutics for the Treatment of Filoviral Infection
por: Murin, Charles D., et al.
Publicado: (2022)

Analysis of neutralizing antibodies to COVID-19 inactivated or subunit recombinant vaccines in hospitalized patients with liver dysfunction
por: Li, Hu, et al.
Publicado: (2023)

Editorial: Insights Into the Etiology, Prevention, and Treatment of Food Allergy
por: Oyoshi, Michiko, et al.
Publicado: (2020)

Editorial: Effector functions of therapeutic antibodies
por: Boross, Peter, et al.
Publicado: (2023)

Pre-Existing Cross-Reactive Antibody Responses Do Not Significantly Impact Inactivated COVID-19 Vaccine-Induced Neutralization
por: Wang, Jin, et al.
Publicado: (2021)

Effectiveness of Monoclonal Antibodies in Preventing Severe COVID-19 With Emergence of the Delta Variant
por: O’Horo, John C., et al.
Publicado: (2022)

Neutralization-Enhancing RF Antibodies for HIV Vaccines
por: Suslov, Konstantin V.
Publicado: (2014)

Neutralizing monoclonal antibodies for treatment of COVID-19
por: Taylor, Peter C., et al.
Publicado: (2021)

Editorial: Contemporary challenges in diagnosis and treatment of predominantly antibody deficiency
por: Ameratunga, Rohan, et al.
Publicado: (2022)

Monoclonal Antibody Therapy for COVID-19 in Solid Organ Transplant Recipients
por: Yetmar, Zachary A, et al.
Publicado: (2021)

Targeted Delivery of Neutralizing Anti-C5 Antibody to Renal Endothelium Prevents Complement-Dependent Tissue Damage
por: Durigutto, Paolo, et al.
Publicado: (2017)

Antibody-Dependent Cellular Cytotoxicity (ADCC)-Mediating Antibodies Constrain Neutralizing Antibody Escape Pathway
por: Mielke, Dieter, et al.
Publicado: (2019)

The Landscape of Neutralizing Monoclonal Antibodies (nAbs) for Treatment and Prevention of COVID-19
por: de Almeida Oliveira, Aline, et al.
Publicado: (2023)

Characterization of RBD-specific cross-neutralizing antibodies responses against SARS-CoV-2 variants from COVID-19 convalescents
por: Wang, Zheng, et al.
Publicado: (2023)

Cross-reactive broadly neutralizing antibodies: timing is everything
por: Euler, Zelda, et al.
Publicado: (2012)

Non-Neutralizing Antibodies Directed against HIV and Their Functions
por: Mayr, Luzia M., et al.
Publicado: (2017)

Antiviral Drugs for Viruses Other Than Human Immunodeficiency Virus
por: Razonable, Raymund R.
Publicado: (2011)

Glycoprotein B Antibodies Completely Neutralize EBV Infection of B Cells
por: Hong, Junping, et al.
Publicado: (2022)

Factors associated with neutralizing antibody levels induced by two inactivated COVID-19 vaccines for 12 months after primary series vaccination
por: Wang, Fuzhen, et al.
Publicado: (2022)

An ADAM17-Neutralizing Antibody Reduces Inflammation and Mortality While Increasing Viral Burden in a COVID-19 Mouse Model
por: Hedges, Jodi F., et al.
Publicado: (2022)

Editorial: Advances in the Prevention and Treatment of Inflammation-Associated Preterm Birth
por: Keelan, Jeffrey A., et al.
Publicado: (2016)

SARS-CoV-2 antibody progression and neutralizing potential in mild symptomatic COVID-19 patients – a comparative long term post-infection study
por: Brehm, Jessica, et al.
Publicado: (2022)

Recombinant COVID-19 vaccine based on recombinant RBD/Nucleoprotein and saponin adjuvant induces long-lasting neutralizing antibodies and cellular immunity
por: Ghaemi, Amir, et al.
Publicado: (2022)

Sequential Analysis of Binding and Neutralizing Antibody in COVID-19 Convalescent Patients at 14 Months After SARS-CoV-2 Infection
por: Rosati, Margherita, et al.
Publicado: (2021)

Editorial: Natural Antibodies in Health and Disease
por: Hernandez, Ana Maria, et al.
Publicado: (2017)

Editorial: The Complexity of Primary Antibody Deficiencies
por: Quinti, Isabella, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_9cusnmho5o4brtal4dinvduo9q